Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 2
2002 1
2003 1
2005 2
2006 2
2007 3
2009 1
2010 1
2012 2
2013 1
2016 1
2018 2
2019 2
2020 1
2021 1
2022 1
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for blind frangou
Your search for Blend Frangu retrieved no results
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study.
Sen A, Akinola M, Tai XY, Symmonds M, Davis Jones G, Mura S, Galloway J, Hallam A, Chan JYC, Koychev I, Butler C, Geddes J, Van Der Putt R, Thompson S, Manohar SG, Frangou E, Love S, McShane R, Husain M. Sen A, et al. Trials. 2021 Jul 31;22(1):508. doi: 10.1186/s13063-021-05404-4. Trials. 2021. PMID: 34332638 Free PMC article. Clinical Trial.
We plan to recruit thirty patients with mild to moderate Alzheimer's disease with no history of previous seizures or other significant co-morbidity. Participants will be allocated to a double-blind placebo-controlled crossover trial that tests levetiracetam against placebo …
We plan to recruit thirty patients with mild to moderate Alzheimer's disease with no history of previous seizures or other significant co-mo …
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Hölscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Femminella GD, et al. Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x. Trials. 2019. PMID: 30944040 Free PMC article. Clinical Trial.
METHODS/DESIGN: ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. ...
METHODS/DESIGN: ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in par …
Mechanism of action for leflunomide in rheumatoid arthritis.
Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ. Fox RI, et al. Clin Immunol. 1999 Dec;93(3):198-208. doi: 10.1006/clim.1999.4777. Clin Immunol. 1999. PMID: 10600330 Review.
Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA). This approval was based on data from a double-blind, multicenter trials in the United States (leflunomide versus methotrexate versus placebo) …
Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA). This appr …
A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression.
Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, Gonda X, Frangou S, Vieta E. Reinares M, et al. Int J Neuropsychopharmacol. 2013 Mar;16(2):485-96. doi: 10.1017/S1461145712000491. Epub 2012 May 10. Int J Neuropsychopharmacol. 2013. PMID: 22575611 Free article. Review.
All anticonvulsants were generally well tolerated. No double-blind RCTs were found for the use of other anticonvulsants such as oxcarbazepine, licarbazepine, zonisamide, retigabine, pregabalin, tiagabine, felbamate and vigabatrine in the acute treatment of bipolar depressi …
All anticonvulsants were generally well tolerated. No double-blind RCTs were found for the use of other anticonvulsants such as oxcar …
Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study.
Frangou S, Lewis M, McCrone P. Frangou S, et al. Br J Psychiatry. 2006 Jan;188:46-50. doi: 10.1192/bjp.188.1.46. Br J Psychiatry. 2006. PMID: 16388069 Clinical Trial.
AIMS: To examine the efficacy of EPA in treating depression in bipolar disorder. METHOD: In a12-week, double-blind study individuals with bipolar depression were randomly assigned to adjunctive treatment with placebo (n=26) or with 1 g/day (n=24) or 2 g/day (n=25) of ethyl …
AIMS: To examine the efficacy of EPA in treating depression in bipolar disorder. METHOD: In a12-week, double-blind study individuals …
Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression.
Severus E, Seemüller F, Berger M, Dittmann S, Obermeier M, Pfennig A, Riedel M, Frangou S, Möller HJ, Bauer M. Severus E, et al. BMC Med. 2012 Jul 2;10:67. doi: 10.1186/1741-7015-10-67. BMC Med. 2012. PMID: 22747667 Free PMC article.
BACKGROUND: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the efficacy of new psychopharmacological interventions in the treatment of major depression. However, the blinded use of placebo has been …
BACKGROUND: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the ef …
Is the prophylactic antidepressant efficacy of lithium in bipolar I disorder dependent on study design and lithium level?
Severus WE, Grunze H, Kleindienst N, Frangou S, Moeller HJ. Severus WE, et al. J Clin Psychopharmacol. 2005 Oct;25(5):457-62. doi: 10.1097/01.jcp.0000177550.13714.7a. J Clin Psychopharmacol. 2005. PMID: 16160621 Review.
To provide evidence-based guidelines on this issue, large prospective, randomized, double-blind, placebo-controlled trials are needed comparing the efficacy of lithium at different plasma levels against manic and depressive relapse/recurrence. ...
To provide evidence-based guidelines on this issue, large prospective, randomized, double-blind, placebo-controlled trials are needed …
Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL. Watson KT, et al. Behav Brain Res. 2019 Jan 1;356:271-278. doi: 10.1016/j.bbr.2018.08.006. Epub 2018 Aug 9. Behav Brain Res. 2019. PMID: 30099030 Clinical Trial.
Liraglutide, a glucagon-like peptide-1 (GLP) agonist, is an insulin-sensitizing agent with neuroprotective properties, as shown in animal studies. The purpose of this double-blinded, placebo-controlled study was to examine the neural effects of administration of liraglutid …
Liraglutide, a glucagon-like peptide-1 (GLP) agonist, is an insulin-sensitizing agent with neuroprotective properties, as shown in animal st …
Effect of moderate to high intensity aerobic exercise on blood pressure in young adults: The TEPHRA open, two-arm, parallel superiority randomized clinical trial.
Williamson W, Lewandowski AJ, Huckstep OJ, Lapidaire W, Ooms A, Tan C, Mohamed A, Alsharqi M, Bertagnolli M, Woodward W, Dockerill C, McCourt A, Kenworthy Y, Burchert H, Doherty A, Newton J, Hanssen H, Cruickshank JK, McManus R, Holmes J, Ji C, Love S, Frangou E, Everett C, Hillsdon M, Dawes H, Foster C, Leeson P. Williamson W, et al. EClinicalMedicine. 2022 May 13;48:101445. doi: 10.1016/j.eclinm.2022.101445. eCollection 2022 Jun. EClinicalMedicine. 2022. PMID: 35706495 Free PMC article.
The control group were sign-posted to educational materials on hypertension and recommended lifestyle behaviours. Investigators performing statistical analyses were blinded to group allocation. The primary outcome was 24 h awake ambulatory blood pressure (systolic and dias …
The control group were sign-posted to educational materials on hypertension and recommended lifestyle behaviours. Investigators performing s …
Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: A meta-analysis of randomized controlled trials.
Kennedy NI, Lee WH, Frangou S. Kennedy NI, et al. Eur Psychiatry. 2018 Mar;49:69-77. doi: 10.1016/j.eurpsy.2017.12.025. Epub 2018 Feb 3. Eur Psychiatry. 2018. PMID: 29413808
BACKGROUND: Transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) have shown promise in the treatment of schizophrenia. OBJECTIVE: To quantify the efficacy of double-blind randomized controlled trials (RCT) of tDCS and rTMS …
BACKGROUND: Transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) have shown promise in the …
22 results